INTRODUCTION: In patients with gastrointestinal (GI) cancer, severe malnutrition is associated
with increased morbidity and mortality, reduction of treatment efficacy, and increased …

Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …

Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …

Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …

Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein
concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in …

Background Sorafenib is the recommended treatment for patients with advanced hepatocellular
carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective …

Background All randomised phase 3 studies of selective internal radiation therapy for advanced
hepatocellular carcinoma published to date have reported negative results. However, …

Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast
growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular …

Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic
therapies for the treatment of advanced hepatocellular carcinoma. Objective To assess the …